Belloni-Fortina Anna, Montesco Maria Cristina, Piaserico Stefano, Bordignon Matteo, Tona Francesco, Feltrin Giuseppe, Alaibac Mauro
Unit of Dermatology, University of Padua, Via Cesare Battisti, Padua, Italy.
Acta Derm Venereol. 2009;89(1):74-7. doi: 10.2340/00015555-0543.
Solid organ transplant recipients are at risk of developing a wide range of viral-associated malignancies, including skin tumours and lymphoproliferative disorders. The risk of a post-transplant lymphoproliferative disorder is 28-49 times the risk of a lymphoproliferative disorder in the normal population. Most cases are of B-cell phenotype and are associated with Epstein-Barr virus infection. Post-transplant lymphoproliferative disorders presenting clinically in the skin are rare and usually of B-cell phenotype. Only rare cases of cutaneous T-cell post-transplant lymphoproliferative disorder have been reported previously, mostly mycosis fungoides type. We describe here a rare primary cutaneous T-cell lymphoma CD30+ arising in a heart transplant patient who had a nodule on the right leg, several years after heart transplantation. The morphology and immunohistochemical findings were consistent with a CD30+ anaplastic large cell lymphoma with a T-cell phenotype. Excisional biopsy and radiotherapy of the affected area were performed. In this patient, the presence of a solitary lesion and the lack of systemic involvement represented the main factors taken into account in choosing the therapy and the patient was therefore treated using a non-aggressive approach, although with systemic immunosuppression. In conclusion, the diagnosis of a CD30+ anaplastic large cell lymphoma in transplant recipients does not imply aggressive clinical behaviour by the lymphoma.
实体器官移植受者有发生多种病毒相关恶性肿瘤的风险,包括皮肤肿瘤和淋巴增殖性疾病。移植后淋巴增殖性疾病的风险是正常人群中淋巴增殖性疾病风险的28至49倍。大多数病例为B细胞表型,与爱泼斯坦-巴尔病毒感染有关。临床上出现在皮肤的移植后淋巴增殖性疾病很少见,通常为B细胞表型。此前仅报道过罕见的皮肤T细胞移植后淋巴增殖性疾病病例,大多为蕈样肉芽肿型。我们在此描述一例罕见的原发性皮肤T细胞淋巴瘤CD30+,发生在一名心脏移植患者身上,该患者在心脏移植几年后右腿出现一个结节。形态学和免疫组化结果与具有T细胞表型的CD30+间变性大细胞淋巴瘤一致。对患区进行了切除活检和放射治疗。在该患者中,存在孤立性病变且无全身受累是选择治疗时考虑的主要因素,因此尽管患者接受全身免疫抑制,但采用了非激进的治疗方法。总之,移植受者中CD30+间变性大细胞淋巴瘤的诊断并不意味着淋巴瘤具有侵袭性的临床行为。